Condition (MeSH)
Lupus Vasculitis, Central Nervous System
ClinicalTrials.gov lists 7 trials for Lupus Vasculitis, Central Nervous System or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
7 of the 7 trials are tagged with Lupus Vasculitis, Central Nervous System itself; the rest are tagged with a narrower condition beneath it.
When did Lupus Vasculitis, Central Nervous System trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2023 | 1 |
| 2020 | 1 |
| 2018 | 1 |
| 2008 | 1 |
| 2007 | 1 |
| 2006 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 7 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Lupus Vasculitis, Central Nervous System trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Not applicable | 2 |
| Observational | 3 |
How many Lupus Vasculitis, Central Nervous System trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 2 |
| Completed | 3 |
| Withdrawn | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Lupus Vasculitis, Central Nervous System trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Evergreen Therapeutics, Inc. | 1 |
| Gilead Sciences | 1 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 1 |
Which publications cover Lupus Vasculitis, Central Nervous System? (22)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trials. | Rheumatology international | 2024 | Yes |
| Glial and axonal changes in systemic lupus erythematosus measured with diffusion of intracellular metabolites. | Brain : a journal of neurology | 2016 | Yes |
| EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres. | Rheumatology (Oxford, England) | 2015 | Yes |
| Diagnosis and management of neuropsychiatric SLE. | Nature reviews. Rheumatology | 2014 | Yes |
| Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus. | Rheumatology international | 2013 | Yes |
Showing 5 of 22 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.